Table 1. Patient characteristics of the CLL cohort from Essen.
| Total | Progranulin low (≤165.5 ng/ml) | Progranulin high (>165.5 ng/ml) | p | ||
| Age | N | 131 | 66 | 65 | 0.542 |
| mean ± SD | 62.02±11.11 | 61.42±10.88 | 62.62±11.40 | ||
| median (range) | 63(31–87) | 63 (37–83) | 63 (31–87) | ||
| Sex | Male | 86 (65.6%) | 40 (46.5%) | 46 (53.5%) | 0.217 |
| Female | 45 (34.4%) | 26 (57.8%) | 19 (42.2%) | ||
| Binet at diagnosis | A | 91 (69.5%) | 53 (58.2%) | 38 (41.8%) | 0.027 |
| B | 24 (18.3%) | 7 (29.2%) | 17 (70.8%) | ||
| C | 15 (11.5%) | 6 (40%) | 9 (60%) | ||
| Missing | 1 (0.8%) | ||||
| IGHV | unmutated | 33 (25.2%) | 8 (24.2%) | 25 (75.8%) | <0.001 |
| mutated | 37 (28.2%) | 26 (70.3%) | 11 (29.7%) | ||
| missing | 61 (46.6%) | ||||
| CD38 | negative (<30%) | 68 (51.9% | 40 (58.8%) | 28 (41.2%) | 0.107 |
| positive (>30%) | 58 (44.3%) | 25 (43.1%) | 33 (56.9%) | ||
| missing | 5 (3.8%) | ||||
| ZAP-70 | negative (<20% | 31(23.7%) | 21 (67.7%) | 10 (32.3%) | 0.027 |
| positive (>20%) | 36 (27.5%) | 14 (38.9%) | 22 (61.1%) | ||
| missing | 64 (48.9%) | ||||
| FISH risk group * | low risk | 96 (73.3%) | 60 (62.5%) | 36 (37.5%) | <0.001 |
| high risk | 33 (25.2%) | 6 (18.2%) | 27 (81.8%) | ||
| missing | 2 (1.5%) | ||||
| β2-microglobulin | N | 74 (56.5%) | 37 | 37 | <0.001 |
| mean ± SD | 3.46±2.18 | 2.45±0.90 | 4.47±2.59 | ||
| median (range) | 2.6 (1.3–11.7) | 2.35 (1.30 - 4.70) | 3.40 (1.93–11.70) | ||
| Leucocytes | N | 85 (64.9%) | 43 | 42 | 0.188 |
| mean ± SD | 57.67±76.76 | 46.8±84.51 | 68.79±67.13 | ||
| median (range) | 26.8 (0.3–539.0) | 20.40 (5.9–539.0) | 42.9 (0.3–272.0) | ||
| Therapy | therapy | 73 (55.7%) | 24 (32.9%) | 49 (67.1%) | <0.001 |
| no therapy | 58 (44.3%) | 42 (72.4%) | 16 (27.6%) | ||
| Survival | Dead | 27 (20.6%) | 5 (18.5%) | 22 (81.5%) | <0.001 |
| Alive | 104 (79.4%) | 61 (58.7%) | 43 (41.3%) |
*
Leukemic samples exhibiting a 17p- and/or 11q- karyotype were assigned to the high risk and samples with either no chromosomal abnormalities or aberrations of chromosomes 13q and 12 to the low risk category. Leukocyte counts and age were assessed at the time of sample acquisition whereas all other risk parameters were determined at the time of diagnosis.